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Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) can infect several cells, replicate in the 48	
central nervous system and affect blood-brain barrier (BBB) integrity. This study aimed to 49	
investigate whether cerebrospinal fluid (CSF) EBV or CMV DNA was associated with viral, 50	
inflammatory and neuronal damage biomarkers in people living with HIV (PLWH).  51	
EBV, CMV DNA and HIV RNA were measured on CSF, through RT-PCR,  from PLWHs 52	
undergoing lumbar punctures for clinical reasons (excluding oncho-haematological 53	
comorbidities). Immune-enzymatic assays evaluated BBB inflammation and damage. Patients 54	
were stratified according to plasma HIV RNA levels in viremic (≥50 copies/mL) and aviremic 55	
(<50 copies/mL). We included 298 participants. Among 167 viremic patients CSF EBV and 56	
CMV DNA were detectable in 42 (25.1%) and 10 (6.3%) participants; among 130 aviremic 57	
subjects CSF EBV and CMV DNA were detectable in 12 (9.2%) and 0 (0%) participants, 58	
respectively. In viremic group detectable CSF EBV DNA was associated with CSF pleocytosis 59	
(p<0.001), higher CSF HIV RNA (p<0.001) and neopterin levels (p=0.002). In aviremic 60	
participants detectable EBV DNA was associated with pleocytosis (p=0.056), higher neopterin 61	
(p=0.027) and immune globulins (p=0.016) in the CSF; CSF escape was more common in those 62	
with detectable EBV DNA (50% vs 21.2%, p=0.036). 63	
EBV DNA was frequently detected in the CSF of viremic and fewer aviremic patients on 64	
antiretroviral treatment. In PLWH without clinical evidence of encephalitis CSF EBV DNA was 65	
associated with higher levels of HIV RNA and biomarkers of neuronal damage/inflammation. 66	
The role of EBV reactivation in HIV-associated CNS disorders warrants further studies. 67	
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The central nervous system (CNS) is a clinically relevant target of HIV and severe forms of 102	
encephalitis and dementia have been described since the beginning of the epidemics [1]. Even 103	
in the current era of antiretroviral therapy (ART), chronic CNS  involvement is a significant issue 104	
for people living with HIV (PLWH) [2].  In fact, HIV persists in the brain tissue of people living 105	
with HIV (PLWH) despite systemic viral control and its detection in the cerebrospinal fluid (CSF) 106	
has been associated with acute/subacute neurological symptoms, worse neurocognitive 107	
performances and immune activation [3].  While the clinical relevance of HIV RNA escape within 108	
the CSF is controversial, symptomatic cases have been described and ART optimizations have 109	
led to clinical/radiological/virologic improvements, thus supporting a pathogenetic role of HIV 110	
RNA active replication in the CNS [4].  The factors associated with HIV RNA escape in the CSF 111	
are poorly understood with several identified risk factors, such as low nadir CD4 cell count, 112	
dementia, poor adherence to ART, low level viremia in blood plasma and the presence of drug 113	
resistance associated mutations [5-6].  Another possible driver of compartmentalized HIV RNA 114	
replication in the CSF might be co-infection with other chronic viruses (“secondary escape”) but 115	
this has not been systematically investigated [7].   116	
As part of this study, we focused on the effects of Cytomegalovirus (CMV) and Epstein-Barr 117	
virus (EBV) since PLWH have a higher risk of acquiring and incompletely controlling both 118	
viruses; both EBV [8-10] and CMV [11-13] have been associated with neurological disorders 119	
as well as vascular inflammation, thus suggesting the potential for chronic CNS and endothelial 120	
involvement (well recognized for CMV) [11-13]. In particular, EBV can infect macrovascular 121	
endothelial cells in human tissue [14-17], human brain micro-vessels [18] and human umbilical 122	








production of pro- inflammatory molecules (CCL-2 and CCL-5) and also hyper-expression of 129	
surface adhesion molecules (ICAM-1 and VCAM-1) with a potential creation of an inflammatory 130	
breach through the Blood Brain Barrier (BBB) [12, 20-21]. This may be relevant because a key 131	
factor in chronic HIV RNA CNS involvement seems to be the alteration of the BBB: the latter 132	
has been recently described as being part of the neurovascular unit where endothelial cells 133	
(and perycites) co-operate with astrocytes and neurons [22]. Thus, CMV and EBV may 134	
potentially cause a sub-clinical chronic infection and facilitate inflammatory cells’ trafficking 135	
through the BBB increasing migration of HIV into the CNS. [7, 15, 23]  136	
 137	
Material and Methods  138	
Cohort and Samples 139	
We enrolled adult PLWH undergoing lumbar punctures for clinical reasons, in a cross-sectional 140	
design study, including late presentation with <100 CD4+ T lymphocytes/mm3 in peripheral 141	
blood, opportunistic infections, new or persistent neurological symptoms (including headache), 142	
worsening cognitive impairment, need of lumbar puncture in case of syphilis or white mater 143	
hyperintensities at brain MRI. Patients with primary central nervous system lymphomas, 144	
lymphoproliferative diseases and autoimmune disorders were excluded from this study. We 145	
also excluded HIV controllers without ART. Demographic, immunovirological, clinical and 146	
therapeutic data were recorded as well as CSF characteristics. The protocol was approved by 147	
our Ethics Committee (Comitato Etico Inter-aziendale di Orbassano, n. 103/2015). Study 148	





Levels of HIV RNA were measured by real time Polymerase Chain Reaction (RT-PCR) assay 152	
CAP/CTM HIV-1 vs. 2.0 (CAP/CTM, Roche Molecular System, Branchburg, NJ, HIV RNA 153	
detection limit: 20 copies/mL). Levels of EBV DNA and CMV DNA were measured through the 154	
RT-PCR (detection limit: 100 copies/mL). CSF escape was defined as CSF HIV RNA >50 155	
copies/mL with plasma HIV RNA <50 copies/mL and CSF/plasma discordance as CSF HIV 156	
RNA 0.5 Log10 higher than plasma HIV RNA (if both were detectable) [24]. 157	
Immunological Measures and BBB Damage  158	
Quantitative determination of albumin in serum and CSF was measured by 159	
Immunoturbidimetric methods (AU 5800, Beckman Coulter, Brea, CA, USA). CSF to serum 160	
albumin ratio (CSAR) was calculated as albumin in CSF (mg/L)/albumin in serum (g/L), and 161	
was used to evaluate BBB permeability. Impaired BBB was defined according to age-adjusted 162	
Reibergrams (normal if below 6.5 in patients aged <40 years and below 8 in patients >40 years) 163	
[25]. The presence of Immune globulins (Ig)G produced inside the CNS was calculated 164	
according to Tibbling index [26]. CSF pleocytosis was defined as ³5 cells/mm3. 165	
CSF total tau (t-tau), phosphorylated tau (p-tau) and 1-42 β-amyloid (Aβ1-42) were measured by 166	
immunoenzymatic methods (Fujirebio diagnostics, Malvern, U.S.A.) with limits of detection of 167	
57, 20 and 225 pg/ml, respectively.  Neopterin and S100B were measured through ELISA [DRG 168	
Diagnostics (Marburg, Germany) and DIAMETRA S.r.l. (Spello, Italy), respectively]. Upper 169	
limits of normality in HIV-negative individuals were as follows: t-tau [<300 pg/mL (in participants 170	
aged 21–50), <450 pg/mL (in participants aged 51–70) or <500 pg/mL in older participants], p-171	
tau (<61 pg/mL), 1–42 beta amyloid (>500 pg/mL), neopterin (<1.5 ng/mL) and S100B (<380 172	





We performed descriptive statistics on the entire study population and then stratified between 176	
study participants with suppressed plasma HIV RNA (<50 copies/mL) and those with detectable 177	
HIV RNA. 178	
Data were analyzed using standard statistical methods: variables were described with medians 179	
[interquartile ranges (IQR)], groups were compared using non-parametric tests (Mann–Whitney, 180	
Kruskal-Wallis and Spearman’s tests as specified in the text). Linear logistic regressions were 181	
used for estimating the association between detectable EBV/CMV DNA, HIV RNA, as well as 182	
biomarker of CNS damage and inflammation. Models were adjusted for CD4+ cell counts and 183	
CSF HIV RNA. Data analysis was performed using PASW software version 22.0 (IBM).  184	
 185	
Results 186	
Two hundred and ninety-seven PLWH were included in this study, of whom 118 (39.4 %) were 187	
naïve for ART. Baseline and immune-virological characteristics, stratified by plasma HIV RNA 188	
(below or above 50 copies/mL) are shown in Table 1.  189	
EBV DNA was detected in the CSF of 42 (25.1%) and 12 (9.2%) participants with detectable 190	
and undetectable HIV RNA in plasma, respectively (p<0.001). Similarly, higher levels of  EBV 191	
DNA were observed in the CSF of participants with detectable plasma HIV RNA (152 vs. <100 192	
copies/mL, p<0.001). Virological, neuronal damage and inflammation biomarkers stratified by 193	
plasma HIV RNA and CSF EBV DNA detection are shown in Table 2.  194	
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CMV DNA was detected only in the CSF of participants with plasma HIV RNA >50 copies/mL 208	
[10 (6.3%) vs. 0 (0%), p=0.006]; participants with detectable CSF CMV DNA had lowerCD4+ T 209	
lymphocytes (25 vs. 91/mm3, p=0.005), higher plasma and CSF HIV RNA (5.8 vs. 5.1 Log10 210	
copies/mL, p=0.039 and 5.0 vs. 3.6 Log10 copies/mL, p=0.016), higher CSAR (9.0 vs. 5.6, 211	
p=0.046) and neopterin (5.4 vs. 2.2 ng/mL, p=0.012) and they were more often diagnosed with 212	
opportunistic infections (40% vs. 17.3%, p=0.093). 213	
 214	
In PLWH with detectable plasma HIV RNA, presence of detectable EBV DNA was associated 215	
with a significantly higher number of cells, greater CSAR, as well as increased HIV RNA and 216	
neopterin in the CSF. In participants with plasma HIV RNA <50 copies/mL, presence of 217	
detectable EBV DNA was associated with significantly higher number of cells and greater 218	
neopterin in the CSF. The presence of IgG produced within the CNS was more common in 219	
aviremic participants with detectable CSF EBV DNA (38% vs. 0%, p=0.036). Additionally, CSF 220	
HIV RNA escape was more common in ART-suppressed participants with detectable EBV DNA 221	
(50% vs. 21%, p=0.036) (Figure 1). 222	
No correlation was observed between EBV DNA concentrations and the studied biomarkers. 223	
Linear logistic analysis (adjusted for CD4 cell count and CSF HIV RNA) suggested that a 224	
detectable EBV DNA was independently associated with CSF pleocytosis in PLWH with CSF 225	
HIV RNA <50 copies/mL (p<0.001) and non-controllers (p<0.001), with neopterin in HIV non-226	
controllers (p=0.015) and with the production of IgG within the CNS in HIV-controllers (p=0.008). 227	
 228	
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To better understand the role of EBV and CMV in the CNS on HIV RNA replication, BBB 234	
damage and biomarkers of neuronal damage/inflammation, we measured levels of CMV and 235	
EBV DNA in CSF of 298 PLWH. 236	
Overall, we observed that EBV DNA was detectable at low levels in 18% of all PLWH and it 237	
was associated with higher levels of HIV RNA in the CSF and up to three-time higher rate of 238	
pleocytosis.  Compared to viremic subjects (25.1%), EBV DNA was found less frequently in 239	
study participants with undetectable HIV RNA in plasma (9.2%), and its presence was 240	
associated with pleocytosis, IgG production within the CNS and presence of CSF HIV RNA 241	
escape. CMV DNA, on the contrary, was found only in HIV viremic participants and was 242	
associated with low CD4+ cell count, high plasma HIV RNA and opportunistic disorders. 243	
Our findings are similar to those reported by Weinberg et al. in HIV-negative individuals where 244	
the presence of pleocytosis was associated with detectable CSF EBV DNA but also presence 245	
of EBV related-mRNA, supporting the hypothesis that EBV DNA is not just carried by latently 246	
infected inflammatory cells (e.g. B cells) but the consequence of actively replicating virus [28]. 247	
Furthermore, EBV affects the immune system and it may enhance neuronal degeneration in 248	
chronic inflammatory conditions [29-30]. Our data are in line with this hypothesis since both 249	
viremic and ART-suppressed PLWH showed higher CSF HIV RNA levels (and CSF to plasma 250	
HIV RNA ratios) and increased white blood cells when EBV DNA was detectable. Additionally, 251	
PLWH with detectable HIV RNA and EBV DNA in CSF also showed higher CSAR supporting 252	
a potential role of chronic EBV infection in BBB damage, which in turn is associated with 253	
ha eliminato: presented 254	
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neurocognitive impairment, and with neuronal damage and inflammation [31-33]. In vitro 255	
experiments suggest that hosting EBV astrocytes and microglia may enhance cell-to-cell 256	
crosstalk and favoring migration of monocytic/macrophagic line cells into the CNS [34-36]. This 257	
effect may be independent from HIV control and immune system improvement: these conditions 258	
have been associated with the absence of neuronal damage and with the lowest CSF 259	
concentrations of neopterin [37-39]. 260	
Despite the low level or absent plasmatic EBV and CMV replication can be found at higher 261	
concentrations in tissues and organs. In a recent study that analyzed 108 gut biopsies collected 262	
from 19 HIV-infected and 22 HIV-uninfected participants, CMV and EBV were detected in more 263	
than 70% of samples but more commonly in HIV-positive subjects [40]. While the negative 264	
effects of sporadic or continuous CMV replication are well-known, there is still uncertainty on 265	
the role of EBV in favoring chronic immune activation. Neuroinflammation, neurodegeneration 266	
and its drivers are widely studied in MS and Late EBV infection seemed to be one of the risk 267	
factors involved in promoting the initial events and the relapses of this chronic neurological 268	
condition [41-42]. In most CSF of MS patients were founded elevated antibody levels against 269	
the entire EBV nuclear antigen (EBNA), and EBNA-1, a protein expressed during latent EBV-270	
infection [43-44]. Anti-EBNA-1 IgG antibodies were correlated also with CSF oligoclonal bands 271	
and in some patients oligoclonal bands include anti-EBV antibodies [45]. Reactivation of EBV 272	
in the central nervous system (CNS) has been proposed as a possible cause of MS although 273	
the virus has not been consistently found in MS lesions [41].  274	
From a broader perspective the lifelong presence of most Herpesviridae in the organism may 275	
produce in some hosts alterations in neuronal cellular processes [46-47]. These observations 276	
were suggested by several studies suggesting an association between EBV, human 277	
ha eliminato: replication 278	
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herpesvirus-1 and 6 (HSV-1 and HHV-6) with Alzheimer’s (AD) and other neurodegenerative 279	
diseases [48-50]. Very recently HHV-6A and HHV-7 produced disruption of molecular, genetic, 280	
and clinical networks was reported in autoptic brains from patients suffering of AD along with 281	
[51-52]. 282	
Additionally, EBV may play a role in suppressing the CNS immune system and therefore 283	
maintain an incomplete T-cell mediated inflammatory response, through the expression of viral 284	
genes encoding for proteins with immunoevasion-like function. This may translate into higher 285	
rates of pleocytosis but with less inflammatory activity [53-54]. On the other hand, ART-286	
suppressed study participants with detectable EBV DNA showed lower CD4+ T cell counts thus 287	
suggesting that immune control may be needed in order to restore a partial control on EBV 288	
replication. 289	
CMV DNA was detected in naïve patients only and, specifically, in patients presenting with 290	
advanced immune depletion and opportunistic infections and with high viral replication both in 291	
plasma and CSF. Additionally, BBB damage and monocyte-derived inflammation were 292	
significantly higher in participants with detectable CSF CMV DNA. Further speculations on the 293	
role of CMV are limited by the low number of participants in this subgroup; yet it may be peculiar 294	
of individuals with very severe immunedeficit and, as already shown by several reports, at 295	
higher risk of poor survival. [55,56] 296	
Some limitations of this study should be acknowledged including the low sample size, the cross-297	
sectional design, the lack of a control group and the lack of plasma EBV DNA measurements. 298	
We also did not collect neurocognitive data in all participants. Importantly, in this observational 299	
study we cannot assess the causal relationship between presence of EBV, inflammation and 300	
HIV RNA escape. Additionally, our cohorts include several patients with very low nadir CD4+ T 301	
12	
	
cell counts and heterogeneous clinical conditions: the same effect may not be observed in 302	
individuals with less advanced disease. 303	
In conclusion we reported for the first time the presence of detectable EBV DNA in the CSF of 304	
PLWH without lympho-proliferative disorders and with no evidence of viral encephalitis.  We 305	
observed that ART-naïve subjects with detectable EBV DNA in the CSF had a higher HIV RNA 306	
viral load and also higher markers of neuronal damage and inflammation; Similarly, in ART-307	
suppressed individuals we observed increased HIV RNA and also evidence of BBB damage, 308	
greater pleocytosis and immune activation. Further studies are warranted for understanding the 309	
contribution of EBV to HIV-associated CNS disorders. 310	
 311	
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